N-nitroso Vilanterol

N-nitroso Vilanterol is a chemical compound that belongs to the class of nitrosamines, which are known to have carcinogenic properties. It is a potent beta2-adrenergic agonist and is used as a bronchodilator to treat conditions like chronic obstructive pulmonary disease (COPD) and asthma. The compound is an active ingredient in several inhalers, including Breo Ellipta, which is a combination of N-nitroso Vilanterol and Fluticasone Furoate. The chemical structure of N-nitroso Vilanterol consists of a nitrosamine group attached to a vilanterol molecule. Nitrosamines are formed by the reaction of nitrites with secondary amines, and they are known to be potent carcinogens. The compound is metabolized in the liver, where it is converted into several metabolites, including N-nitroso Vilanterol, which is the primary active metabolite. However, the safety of N-nitroso Vilanterol has come under scrutiny due to its potential carcinogenic properties. Nitrosamines have been shown to cause cancer in animals and are classified as probable human carcinogens by the International Agency for Research on Cancer (IARC). Therefore, regulatory agencies like the US Food and Drug Administration (FDA) have set limits on the amount of nitrosamines allowed in pharmaceutical products. In conclusion, N-nitroso Vilanterol is a potent bronchodilator used to treat respiratory conditions, but its safety is still being evaluated due to its potential carcinogenic properties.